Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.

Teva vs. Supernus: SG&A Cost Strategies Unveiled

__timestampSupernus Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014724710005078000000
Thursday, January 1, 2015892040004717000000
Friday, January 1, 20161060100005096000000
Sunday, January 1, 20171379050004986000000
Monday, January 1, 20181598880004214000000
Tuesday, January 1, 20191584250003806000000
Wednesday, January 1, 20202006770003671000000
Friday, January 1, 20213047590003528000000
Saturday, January 1, 20223772210003445000000
Sunday, January 1, 20233363610003498000000
Monday, January 1, 20243702000000
Loading chart...

Unveiling the hidden dimensions of data

Optimizing SG&A Costs: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Teva Pharmaceutical Industries Limited and Supernus Pharmaceuticals, Inc. have shown contrasting strategies in optimizing these costs. Teva, a global leader, has seen a significant reduction in SG&A expenses, dropping from 5.08 billion in 2014 to 3.50 billion in 2023, a 31% decrease. This reflects their strategic cost-cutting measures amidst industry challenges. Meanwhile, Supernus, a smaller player, has increased its SG&A spending from 72 million to 336 million, a 366% rise, indicating aggressive investment in growth and market expansion. This divergence highlights the different paths companies can take in managing operational costs, with Teva focusing on efficiency and Supernus on expansion. Understanding these strategies offers valuable insights into the financial health and strategic priorities of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025